Company news
Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd. Class A (SSE:688336) news
Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd. Class A news releases on 6ix. Latest, Sep 25, 2026: "Sunshine Guojian Pharmaceutical (Shanghai) Co.…
View Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd. Class A →
Press releases & updates
"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd."Announcement on Resolutions of the 19th Meeting of the 5th Board of Directors
September 24, 2026
"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 7, 2026
Sunshine Guojian Releases 2026 Interim Report:
August 20, 2026
"Sunshine Guojian Pharmaceutical(Shanghai)Co., Ltd."Announcement on the Listing and Trading of the Shares Vested during the First Vesting Period of the Initial Grant under the 2024 Restricted Stock Incentive Plan
July 7, 2026
"Sunshine Guojian Pharmaceutical(Shanghai)Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
July 1, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 11, 2026
Announcement on Serious Abnormal Fluctuations in Stock Trading
May 19, 2026
Report for Q1 2026
April 24, 2026
Announcement on Expanding Business Scope and Amending "Articles of Association"
April 14, 2026
Announcement on Changing Audit Institution for 2026
April 10, 2026
Announcement on Resolutions of the 14th Meeting of the 5th Board of Directors
March 30, 2026
Announcement on Equity Change of Shareholders Reaching 1% Scale and Results of Shareholding Reduction
February 27, 2026
Announcement on Voluntary Disclosure of New Drug Application Acceptance for the Recombinant Anti-IL-4Rα Humanized Monoclonal Antibody Injection
February 25, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 24, 2026
Announcement on Voluntary Disclosure of the Approval of the New Drug Marketing Application for Anmuqita Monoclonal Antibody Injection
February 13, 2026
Earnings Preannouncement for 2025
January 26, 2026
Announcement on Vesting Results of the 1st Vesting Period for the Initial Grant of the 2024 Restricted Stock Incentive Plan
January 16, 2026
Announcement on Changes in Core Technical Personnel
December 16, 2025
Announcement on Shareholding Reduction Plan for Shareholders
November 9, 2025
Announcement on Abnormal Fluctuations in Stock Trading
November 3, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
October 31, 2025
Report for Q3 2025
October 23, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 20, 2025
Announcement on Receiving Dividends from Joint-stock Company
October 13, 2025
Announcement on Resolutions of the 12th Meeting of the 5th Board of Directors
September 26, 2025
Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025
September 15, 2025
Announcement on 2025 Interim Profit Distribution Plan
August 29, 2025
Announcement on Resignation of Independent Director upon Expiration of Term
August 22, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
August 11, 2025
Announcement on Official Effectiveness of the License Agreement Signed with Pfizer for Project 707 and Related Party Transaction
July 24, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
July 11, 2025
Announcement on Resolution of the 6th Meeting of the 5th Board of Supervisors
June 25, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 6, 2025
Announcement on Resolution of the 2nd Extraordinary General Meeting in 2025
June 5, 2025
Announcement on Using Surplus Funds from Some Projects to Temporarily Supplement Current Capital and Adjusting the Amount of Raised Funds to be Invested in Some Investment Projects Financed by Raised Funds
May 26, 2025
Announcement on Abnormal Fluctuations and Serious Abnormal Fluctuations in Stock Trading
May 22, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
May 20, 2025
Report for Q1 2025
April 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
April 15, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials
April 3, 2025
Announcement on Resolutions of the 3rd Meeting of the 5th Board of Supervisors
March 25, 2025
Announcement on Convening the 1st Extraordinary General Meeting in 2025
March 7, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
February 19, 2025
Annual Earnings Preannouncement for 2024
January 16, 2025
Announcement on Voluntary Disclosure of Notice of Acceptance for Drug Clinical Trial Application Obtained by the Company's SSGJ-627 Injection
January 9, 2025
Announcement on Change of Secretary of the Board of Directors
January 3, 2025
Announcement on Convening the Q3 2024 Performance Briefing
November 18, 2024
Report for Q3 2024
October 22, 2024
Announcement on Implementation of Semi-annual Dividend Distribution in 2024
September 20, 2024